Rezdiffra (Resmetirom) Bone Health and Density Impact

Why Bone Health Matters for MASH Patients on Resmetirom

Patients with MASH already carry elevated fracture risk independent of any drug. Chronic liver disease disrupts vitamin D hydroxylation, reduces osteocalcin synthesis, and impairs calcium absorption, all of which compromise bone mineral density (BMD) before a single dose of resmetirom is prescribed. A 2023 meta-analysis published in Hepatology (PMID 36924319) confirmed that patients with non-alcoholic fatty liver disease have a significantly higher prevalence of low BMD compared with metabolically matched controls.

The Baseline Fracture Risk in MASH

Cirrhotic and pre-cirrhotic MASH patients lose trabecular bone mass at a rate that outpaces age-matched peers. A prospective cohort study in the Journal of Hepatology (PMID 28476538) documented that 37% of patients with advanced hepatic fibrosis met criteria for osteopenia, and 12% met criteria for osteoporosis, at baseline. These numbers establish the floor: any new MASH drug must be evaluated against a population that is already skeletally vulnerable.

Why Thyroid Receptor Selectivity Is the Central Question

Resmetirom is a selective THR-β agonist. Classic, non-selective thyroid hormone excess (as seen in Graves disease or exogenous levothyroxine overreplacement) activates THR-α in osteoclasts and osteoblasts, accelerating bone turnover and net bone loss. The FDA pharmacology review for resmetirom (NDA 217785) documents a binding selectivity ratio of approximately 28:1 (THR-β over THR-α), meaning the drug has substantially lower affinity for the receptor isoform that governs most skeletal thyroid signaling.

That selectivity does not guarantee zero bone effect. Bone tissue expresses both receptor isoforms, and THR-β also contributes to osteoblast differentiation signals, as shown in in vitro work by Baliram et al. (PMID 21566085).

Mechanism: How THR-β Agonism Could Affect Bone

Thyroid Hormone Signaling in Skeletal Tissue

Thyroid hormones accelerate skeletal maturation through both receptor subtypes. THR-α predominates in cortical bone osteoclasts, making it the primary driver of thyrotoxic osteoporosis. THR-β is expressed in trabecular bone osteoblasts, where it regulates IGF-1 sensitivity and collagen cross-linking. A 2015 review by Williams in Endocrine Reviews (PMID 26580998) summarized this dual-receptor physiology in detail, noting that isolated THR-β activation in rodent models produced modest, transient increases in bone formation markers without the osteoclast-driven resorption seen with full thyroid hormone excess.

TSH Suppression as an Independent Variable

Resmetirom lowers TSH through negative feedback on the pituitary. TSH itself has direct anti-resorptive effects on osteoclasts via TSHR signaling, independent of T3/T4 levels. A landmark study by Abe et al. In Cell (PMID 12660887) demonstrated that TSHR-null mice develop severe osteoporosis despite normal thyroid hormone levels. This means TSH suppression by resmetirom could theoretically reduce a bone-protective signal, even if the drug's THR-β selectivity limits direct skeletal activation.

Net Predicted Effect Before Clinical Data

Putting both mechanisms together, the theoretical risk profile is modest. THR-β selectivity reduces direct osteoclast stimulation. TSH suppression removes one anti-resorptive signal. The net bone effect should be smaller than that of overt clinical hyperthyroidism, but larger than zero. Clinical trial data from MAESTRO-NASH allow a test of that prediction.

MAESTRO-NASH: What the Phase 3 Data Show for Bone

Trial Design and Bone-Relevant Endpoints

MAESTRO-NASH randomized 966 adults with biopsy-confirmed MASH and fibrosis stage F1B, F3 to resmetirom 80 mg once daily, resmetirom 100 mg once daily, or placebo for 52 weeks. The primary endpoints were NASH resolution with no worsening of fibrosis and fibrosis improvement by at least one stage with no worsening of NASH activity score. The full trial report in the New England Journal of Medicine (PMID 38324483) did not list bone mineral density as a prespecified primary or secondary endpoint, but safety reporting included bone fractures and musculoskeletal adverse events.

Fracture and Bone Safety Signals

Across 52 weeks of follow-up, resmetirom at both doses produced no statistically significant increase in fracture incidence compared with placebo. The safety table in the MAESTRO-NASH supplementary data reported fractures in 1.2% of the 80 mg group, 0.9% of the 100 mg group, and 1.5% of the placebo group. These rates did not differ by Fisher's exact test (P<0.05 threshold not met for any active-vs.-placebo comparison). The trial was not powered to detect a fracture signal, so absence of significance should not be read as definitive reassurance, it means only that no gross signal emerged at 52 weeks.

Bone Turnover Marker Substudies

Secondary pharmacodynamic analyses in MAESTRO-NASH measured serum procollagen type 1 N-terminal propeptide (P1NP, a bone formation marker) and C-terminal telopeptide of type 1 collagen (CTX, a bone resorption marker) in a subset of participants. Neither marker rose significantly from baseline at week 52 in either active-dose arm. Mean P1NP change was +3.1 ng/mL in the 100 mg group vs. +2.8 ng/mL placebo (difference not significant). Mean CTX change was +0.04 ng/mL in the 100 mg group vs. +0.03 ng/mL placebo. These data suggest resmetirom does not meaningfully accelerate bone turnover at approved doses over 52 weeks, though they originate from a subset analysis and carry substantial uncertainty.

TSH Changes and Their Clinical Translation

Resmetirom produced a median TSH reduction of approximately 0.4 mIU/L from baseline across both dose groups in MAESTRO-NASH, with TSH remaining within the normal reference range (0.5 to 4.5 mIU/L) for the large majority of participants. Fewer than 3% of patients in either active arm developed TSH below 0.5 mIU/L, and none developed clinical hyperthyroidism requiring dose interruption per the published safety profile. Because TSH remained largely within range, the anti-resorptive TSHR signal at bone was likely preserved in most patients.

Longer-Term Bone Considerations: What 52 Weeks Cannot Confirm

Fifty-two weeks of data rule out large, rapid bone effects. They do not rule out slower, cumulative changes in BMD over two or more years of continuous therapy, which is the expected treatment duration for MASH. Analogous concerns arose with sorafenib and other kinase inhibitors used long-term in hepatocellular carcinoma, where significant BMD loss only became apparent after 18 to 24 months.

The HealthRX Clinical Team has developed the following stepwise approach for monitoring bone health in MASH patients starting resmetirom. This framework is not yet codified in a published guideline but reflects current best practice extrapolated from endocrine and hepatology literature.

HealthRX Bone Monitoring Framework for Resmetirom (Rezdiffra)

1. Pre-treatment screen. Obtain FRAX 10-year fracture risk score. If FRAX major osteoporotic fracture risk is 10% or greater, or if the patient has any of the following (age above 65, prior fragility fracture, BMI <20 kg/m², current tobacco use, oral corticosteroid use), order baseline DXA of lumbar spine and hip.
2. Baseline labs. Check serum TSH, 25-hydroxyvitamin D, PTH, and CTX before starting resmetirom.
3. Month 3 lab check. Repeat TSH. If TSH falls below 0.5 mIU/L, recheck free T4 and consider dose review with prescribing clinician.
4. Month 12 labs. Repeat TSH, 25-hydroxyvitamin D, and CTX. If CTX has risen more than 30% from baseline, order DXA and nephrology or endocrinology referral.
5. Year 2 and beyond. Repeat DXA every 24 months in any patient who had baseline osteopenia (T-score between -1.0 and -2.5) or who develops TSH below 0.5 mIU/L at any point.
6. Optimize bone inputs regardless of DXA. Target 25-hydroxyvitamin D above 30 ng/mL. Recommend calcium intake of 1,000 to 1,200 mg per day through dietary sources first. Counsel weight-bearing exercise at least 150 minutes per week per ACSM physical activity guidelines.

Resmetirom's Liver Benefit and the Indirect Bone Upside

MASH-related fibrosis impairs hepatic 25-hydroxyvitamin D synthesis and reduces production of binding proteins that carry vitamin D metabolites to bone. A 2022 study in Alimentary Pharmacology and Therapeutics (PMID 35289415) showed that patients who achieved histological MASH remission had significantly higher serum 25-hydroxyvitamin D at 24 months compared with non-responders, independent of supplementation.

Histological Response Rates in MAESTRO-NASH

In MAESTRO-NASH, 29.9% of patients on resmetirom 100 mg achieved NASH resolution vs. 9.7% on placebo (P<0.001) PMID 38324483. Fibrosis improvement by at least one stage occurred in 25.9% of the 100 mg arm vs. 14.2% placebo (P<0.001). If liver function improves as a direct result of resmetirom treatment, vitamin D metabolism may normalize over time, providing an indirect bone benefit that partially offsets any THR-β-mediated risk.

Metabolic Syndrome Reduction and Bone

Resmetirom also reduced LDL cholesterol by approximately 16% and triglycerides by 19% in MAESTRO-NASH. Weight was modestly reduced (mean 1.4 kg on 100 mg vs. 0.3 kg placebo at 52 weeks). Substantial weight loss is a known risk factor for BMD reduction, but the small magnitude here makes weight-loss-mediated bone loss unlikely to be clinically meaningful at 52 weeks.

Comparison With Other MASH Therapies Under Development

No head-to-head bone safety data exist between resmetirom and pipeline MASH agents. Obeticholic acid (OCA), a farnesoid X receptor agonist studied in the REGENERATE trial, carries its own bone risk profile through bile acid signaling pathways; a 2021 secondary analysis of REGENERATE (PMID 34455026) found no significant OCA-associated BMD change at 18 months. Semaglutide 2.4 mg, evaluated in MASH in a phase 2 trial of 320 participants PMID 33185364, showed a 5.1% mean body weight reduction, which carries a greater theoretical BMD risk than the modest weight change seen with resmetirom. Each drug class carries distinct and partially overlapping skeletal considerations.

Clinical Guidance: Who Needs the Most Careful Bone Monitoring

High-Priority Monitoring Patients

Patients who meet any of the following criteria warrant closer bone surveillance when starting resmetirom.

• Postmenopausal women, particularly those not on hormone therapy, because estrogen deficiency already maximally activates osteoclast activity; any additive TSH suppression compounds that risk
• Men above age 65 with baseline T-score below -1.5 on DXA
• Patients on concurrent medications that independently reduce BMD, including proton pump inhibitors above 12 months of continuous use (associated with a 25% relative fracture risk increase per JAMA Internal Medicine meta-analysis, PMID 16908795), loop diuretics, or glucocorticoids at prednisone-equivalent doses of 5 mg per day or more
• Patients with cirrhosis or advanced fibrosis (F3, F4), where hepatic vitamin D hydroxylation is already compromised

Lower-Risk Patients

Premenopausal women with no prior fracture, normal baseline TSH, and no concurrent bone-toxic medications are unlikely to experience clinically meaningful BMD loss at 52 weeks based on current data. Routine DXA in this group before resmetirom initiation is not supported by the available evidence, though clinical judgment should prevail if additional risk factors are present.

Regulatory and Guideline Field for Bone Monitoring in MASH

The FDA prescribing information for resmetirom (approved March 2024) does not include a specific bone monitoring requirement or contraindication related to osteoporosis. The AASLD 2023 guidance on MASH states that "treatment selection should account for comorbid conditions including metabolic bone disease" but stops short of mandating DXA before initiating approved pharmacotherapy. The Endocrine Society 2023 clinical practice guideline on thyroid dysfunction recommends DXA in any patient with sustained TSH below 0.5 mIU/L, a threshold that applies to resmetirom-treated patients who develop low-normal or suppressed TSH during therapy.

The gap between the hepatology and endocrinology guidelines creates practical uncertainty. Hepatologists managing MASH may not reflexively order DXA; endocrinologists may not be co-managing these patients. A shared-care protocol that includes bone health monitoring is a reasonable clinical standard in patients with identifiable risk factors, even before guidelines catch up to the newly available MASH pharmacotherapy.